Contents 2 min read

Claim and source comparison

Noopept: rat hippocampus, a patient trial and a US warning about a specific product.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Animal study

In the 2008 experiment, NGF and BDNF mRNA levels rose in the hippocampus of rats given Noopept.

Gene expression measurements do not establish effects on memory or clinical neuroprotection in humans.

Source 1 · Full text read

Human randomized controlled trial

In the 2009 report, 53 patients with cognitive impairment of vascular or traumatic origin were randomized to Noopept or piracetam. Of these, 41 completed the 56-day trial. Some scale scores improved from baseline.

The small trial had no placebo arm, and 12 patients did not finish. It does not establish benefit in healthy people or dose equivalence between the two drugs.

Source 2 · Full text read

Regulatory scientific assessment

In a 2019 warning letter, the FDA treated one seller’s Noopept product as an unapproved new drug for the uses claimed in its marketing.

The letter addresses a specific product and its marketing claims. It does not determine approval status for other products or countries.

Source 6 · Official summary read

Our evidence and source methodology

noopept: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Noopept?

Noopept is a synthetic dipeptide derivative. Neurotrophic and glutamate mechanisms are mainly based on animal or cell experiments. Limited studies in patients do not establish benefit in healthy people or clinical efficacy 1000 times greater than piracetam.

Mechanism of Effect

Ostrovskaya et al. (2008) studied single-dose and 28-day Noopept administration in rats. NGF and BDNF mRNA increases were reported in the hippocampus; cortical levels after a single dose were below control, with only a slight BDNF increase during chronic treatment. These animal data do not demonstrate human neurotrophic benefit or a persistent “trace effect” after stopping the medicine.

Clinical Evidence

In the 2009 report, 53 patients with cognitive impairment of vascular or traumatic origin were randomized to Noopept or piracetam. Of these, 41 completed the 56-day trial. Some scale scores improved from baseline.

The small trial had no placebo arm, and 12 patients did not finish. It does not establish benefit in healthy people or dose equivalence between the two drugs.

Dose information and research limits

A safe starting dose, sublingual use, onset of effect or a 56 days on/4 weeks off schedule has not been established for Noopept in healthy people. A short half-life does not guarantee safety; adding choline to prevent headache is also unsupported by controlled human evidence.

Safety and Side Effects

In the Noopept arm, 2 patients left the trial after blood pressure rose and required treatment. This small trial cannot establish the general frequency of adverse effects.

In a 2019 warning letter, the FDA treated one seller’s Noopept product as an unapproved new drug for the uses claimed in its marketing.

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

Sources

  1. Ostrovskaya, R.U. et al. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bulletin of Experimental Biology and Medicine, 146(3), 334–337. PubMed · PMID 19240853
  2. Neznamov, G.G. & Teleshova, E.S. (2009). Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neuroscience and Behavioral Physiology, 39(3), 311–321. PubMed · PMID 19234797
  3. Gudasheva, T.A. et al. (1997). The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. European Journal of Drug Metabolism and Pharmacokinetics, 22(3), 245–252. PubMed · PMID 9358206
  4. Pelsman, A. et al. (2003). GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. International Journal of Developmental Neuroscience, 21(3), 117–124. PubMed · PMID 12711349
  5. Ostrovskaya RU, et al. (2014). Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. Journal of Biomedical Science, 21(1), 74. PubMed · PMID 25096780
  6. US Food and Drug Administration. (2019). Warning Letter: Peak Nootropics LLC aka Advanced Nootropics. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019 US Food and Drug Administration

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions